| Similar Articles |
|---|
 |
The Motley Fool
December 15, 2011
Anders Bylund |
BioSante Pharmaceuticals' Shares Died: What You Need to Know Is this meaningful, or just another movement for BioSante Pharmaceuticals?   |
The Motley Fool
December 14, 2011
David Williamson |
BioSante Investors: It Was Nice While It Lasted Libigel loses to placebo in two studies, shares down 75% after hours. |
The Motley Fool
January 29, 2008
Brian Lawler |
BioSante's Gamble Against Generics BioSante releases more information on the pivotal studies for its lead drug. |
The Motley Fool
February 14, 2011
Brian Orelli |
This Biotech Is Heating Up Biosante Pharmaceuticals was up more than 9% at one point today after the company said the independent Data Monitoring Committee believed Biosante's female sexual dysfunction drug, LibiGel, was safe enough to allow the trial to continue. |
The Motley Fool
July 13, 2011
Brian Orelli |
BioSante Is Ready for Some Action Investors are opening positions in BioSante in anticipation of the release of company data from two clinical trials for its female sexual-dysfunction treatment, LibiGel, by the end of the year. |
The Motley Fool
May 14, 2007
Brian Lawler |
Biosante's Lame Deal Last week, shares of the drugmaker were up 8% after the company announced that it had signed a drug development deal with a tiny European pharma, Pantarhei. |
The Motley Fool
December 15, 2011
Brian Orelli |
BioSante Shares Crushed by Placebo Effect BioSante's LibiGel efficacy is not deemed statistically significant. |
The Motley Fool
December 21, 2011
Brian Orelli |
Knocked Down? Not for Long! Last week shares of Antares Pharma got knocked down after BioSante Pharmaceuticals' LibiGel didn't live up to expectations. |
The Motley Fool
August 31, 2011
Brian Orelli |
3 Biotechs Ready to Move Here are three biotechs with upcoming events that could drive their value higher: Exelixis... BioSante Pharmaceuticals... Amylin Pharmaceuticals... |
The Motley Fool
July 28, 2011
Brian Orelli |
But, But, But, I Thought You Were for Sale? BioSante raises cash -- guess it's not on the market. |
The Motley Fool
July 28, 2011
Travis Hoium |
Corn Products International Shares Plunged: What You Need to Know Shares of Corn Products International fell as much as 13% in intraday trading today after the company released earnings. |
The Motley Fool
November 16, 2011
David Williamson |
3 Biotechs Beating the Market The daily health-care news investors need to read. |
The Motley Fool
July 22, 2011
Brian Orelli |
That's All the Melanoma Market Is Worth? BioSante licenses out its melanoma vaccine for $100,000. |
The Motley Fool
October 13, 2010
Travis Hoium |
Keryx Biopharmaceuticals Shares Popped: What You Need to Know Keryx Biopharmaceuticals Inc. shares jumped 10% in intraday trading today, on over three times the average volume for the last three months. |
The Motley Fool
June 23, 2010
Kris Eddy |
Drugmakers Finally Recognize the Next Big Opportunity Drug companies seem to be increasing efforts to address female health problems. |
The Motley Fool
December 15, 2011
David Williamson |
1 Massive Biotech Bloodbath Trial results and FDA panels ruled the health-care sector today. |
The Motley Fool
October 14, 2011
Sean Williams |
7 FDA Decisions You Can't Afford to Ignore in Q4 These stocks are bound to move as the FDA weighs in on their prospective drugs in Q4: Bristol-Myers... BioSante... Teva... Regeneron... Transcept... Incyte... Antares Pharma... |
CFO
October 1, 2009
Sarah Johnson |
Buying Cash That was one CFO's solution for keeping his small company afloat as it waits for regulatory approval of its product and continues to burn through funds. |
The Motley Fool
May 20, 2011
Travis Hoium |
Camelot Information Systems Shares Popped: What You Need to Know Shares of Camelot Information Systems jumped as much as 16% briefly in a spike early in intraday trading Friday after quarterly revenue beat expectations. |
The Motley Fool
August 19, 2011
Cindy Johnson |
12 Biotech Stocks the Insiders Are Buying Folks in the know think these biotech stocks will rise. Should you join them? |
The Motley Fool
November 29, 2011
Brian Orelli |
Every Biotech Is for Sale It just depends on the right price. |
Salon.com
October 26, 2000
Barbara Raab |
The vagina dialogues Hundreds of doctors gather in Boston for their annual gabfest about women's sexual dysfunction -- but some of their colleagues say they're misguided... |
The Motley Fool
June 28, 2011
Eric Bleeker |
Where Is Teva Pharmaceuticals Finding Growth? Teva should see its sales continue to climb, especially in already booming international markets. |
The Motley Fool
December 27, 2006
Brian Lawler |
Bradley's Mediocre Drug Approval With the FDA's approval of Bradley's Elestrin, shares were up over 10% upon approval last week. |
